DDW 2022 Conference Coverage


 

Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From The Phase 3 LUCENT-2 Study

431 views
June 29, 2022
Mirikizumab was approved by the FDA on October 26, 2023
Comments 0
Login to view comments. Click here to Login